PMID- 25119920
OWN - NLM
STAT- MEDLINE
DCOM- 20141006
LR  - 20221207
IS  - 1003-9406 (Print)
IS  - 1003-9406 (Linking)
VI  - 31
IP  - 4
DP  - 2014 Aug
TI  - [Detection of p53 gene deletion in Xinjiang patients with chronic lymphocytic 
      leukemia by fluorescence in situ hybridization and its clinical significance].
PG  - 499-503
LID - 10.3760/cma.j.issn.1003-9406.2014.04.020 [doi]
AB  - OBJECTIVE: To investigate the presence of p53 gene deletion in Xinjiang patients 
      with chronic lymphocytic leukemia and its clinical significance. METHODS: 
      Interphase fluorescence in situ hybridization (FISH) was used to detect the p53 
      gene deletion in 77 patients with CLL. Presence of the deletion and its 
      association with clinical and laboratory features as well as prognostic factors 
      were analyzed. Kaplan-Meier method was used to calculate survivals, and the 
      results were compared using a Log-rank test. RESULTS: p53 gene deletion was found 
      in 10 (12.9%) of the patients but none from the control group (P<0.05). The 
      deletion was found in 12.5% (4/32) of ethnic Hans and 13.3% (6/45) of ethnic 
      Uyghurs (P>0.05). No significant different distribution of p53 gene deletion was 
      found in regard to sex, age, ethnicity, peripheral blood cell count (except for 
      Hb) or the levels of lactate dehydrogenase, beta2-micro globulin and CD38 (P>0.05). 
      The deletion rate was higher in the group with high expression of ZAP-70 and 
      patients with advanced stage disease than that in the group of low expression and 
      early-stage CLL (P<0.05). Among 20 patients who received fludarabine therapy, the 
      overall remission rate for those with p53 gene deletion (20%) was lower than 
      those without (75%) (P<0.05). With a median follow-up time of 39.0 (8.0-136.0) 
      months, 11 cases had died (14.3%), among them, 7 cases died from CLL and related 
      complications, and all of them were founded p53 gene deletion. In patients with 
      p53 gene deletion, the progression-free survival (18 months) was shorter than 
      those without the deletion (55 months) (P<0.05). CONCLUSION: The p53 gene 
      deletion has been found in more than 10% of patients with CLL, and the deletion 
      rate did not significantly differ between ethnic Han and Uyghur patients. The 
      deletion is associated with advanced stage of the disease. High-level ZAP-70 
      expression and the presence of p53 deletion are associated with shorter survival 
      and poor response to fludarabine containing therapy. Therefore, drugs affecting 
      the p53 signaling pathway should be avoided.
FAU - Maimaitili, Yimamu
AU  - Maimaitili Y
AD  - Department of Hematology, People's Hospital of Xinjiang Uyghur Autonomous Region, 
      Urumqi, Xinjiang 830001, P.R. China. wangxiaoming@medmail.com.cn.
FAU - Guzailinuer, Wufuer
AU  - Guzailinuer W
FAU - Wang, Xiaomin
AU  - Wang X
FAU - Liu, Hong
AU  - Liu H
FAU - Li, Yan
AU  - Li Y
FAU - Xiao, Meng
AU  - Xiao M
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Yi Chuan Xue Za Zhi
JT  - Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese 
      journal of medical genetics
JID - 9425197
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.2 (ZAP-70 Protein-Tyrosine Kinase)
RN  - EC 2.7.10.2 (ZAP70 protein, human)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Asian People/ethnology/genetics
MH  - Female
MH  - *Gene Deletion
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/drug therapy/ethnology/*genetics
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Tumor Suppressor Protein p53/*genetics
MH  - Vidarabine/analogs & derivatives/therapeutic use
MH  - ZAP-70 Protein-Tyrosine Kinase/genetics
EDAT- 2014/08/15 06:00
MHDA- 2014/10/07 06:00
CRDT- 2014/08/15 06:00
PHST- 2014/08/15 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2014/10/07 06:00 [medline]
AID - 940631106 [pii]
AID - 10.3760/cma.j.issn.1003-9406.2014.04.020 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Aug;31(4):499-503. doi: 
      10.3760/cma.j.issn.1003-9406.2014.04.020.